0334 GMT - Telix Pharmaceuticals' US$2.35 billion acquisition of ITM gives the Australian company unparalleled exposure to the supply chain for cancer treatments' dominant therapeutic isotope, Bell Potter analyst John Hester says. Hester highlights to clients in a note ITM's position as a leading manufacturer of isotopes including 177Lu, which he points out is used in treatments including Novartis's Pluvicto. With margins on ITM's isotope production well in advance of TLX's margins on its manufacturing, his initial view is that the acquisition makes a lot of strategic sense. Bell Potter is reviewing its forecasts for Telix and its target price on the stock. Shares are down 5.1% at 16.94 Australian dollars.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.